medigraphic.com

2014, Number 1

<< Back Next >>

Cir Cir 2014; 82 (1)

Anatomopathological findings during development of diabetic cardiomyopathy in rats

Manjarrez-Gutiérrez G, Hernández-Chávez V, Neri-Gómez T, Boyzo-Montes de Oca A, Mondragón-Herrera JA, Hernández-Rodríguez J

Language: Spanish
References: 35
Page: 11-19
PDF size: 407.11 Kb.


ABSTRACT

Background: The diabetic cardiomyopathy occurs in both type 1 and type 2 diabetes mellitus. Hyperglycemia and associated metabolic changes participate in the pathogenesis of this disease.
Objective: To characterizes various pathological changes occurring during the development of diabetic cardiomyopathy in rats.
Methods: Diabetic rats were used for streptozotocin administration. At 7, 14, 21 and 30 days after toxic administration, the heart was obtained and placed in a Hartman solution and 4% p-formaldehyde. Five-µmthick sections were stained with hematoxylin-eosin, Masson trichrome and immunocytochemistry using anti-β-tubulin antibody.
Results: At 14 days after application of streptozotocin, dilated sinusoids with endothelial lining in the myocardium and collagen deposits in the cardiac interstitium and between the Purkinje fibers were observed. At 21 days there was a slight decrease of the arteriolar lumen due to hyperplasia of the medial layer. It is important to note that cardiac sinusoids as well as collagen deposits became more evident at 30 day of the study, as well as a major derangement of the microtubular system of the cardiomyocytes.
Conclusions: Cardiac sinusoids representing fetal vascular pattern and interstitial fibrosis in the myocardium and the microtubular derangement of cardiomyocytes support the fact that the pathophysiological mechanism of diabetic cardiomyopathy begins in the coronary microcirculation due to changes in cardiac metabolism, contributing to the development of myocardial dysfunction in diabetes.


REFERENCES

  1. Cases A. Enfermedad macro y microvascular en diabetes mellitus tipo 2. Nefrología 2002;22:406-411.

  2. Taegtmeyer H, McNulty P, Young ME. Adaptation and Maladaptation of the Heart in Diabetes: Part I: General Concepts. Circulation 2002;105:1727-1733.

  3. Thierer J. Insuficiencia cardiaca y diabetes. Rev Argent Cardiol 2006;74:60-67.

  4. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial Cell Death in Human Diabetes. Cir Res 2000;87:1123-1132.

  5. Nessler J, Skrzypek A. Diabetic cardiomyopathy: current views on the diagnosis and treatment. Folia Cardiol 2006;13:550-556.

  6. Bell DSH. Diabetic Cardiomyopathy. Diabetes Care 2003;26:2949-2951.

  7. Galderisi M. Diastolic Dysfunction and Diabetes Cardiomyopathy. Evaluation by Doppler Echocardiography. J Am Coll Cardiol 2006;48:1548-1551.

  8. Batista Álvarez ME, Lice Puig M. Enfermedad Muscular Cardiaca Diabética. Rev Cubana Endocrinol 1988;9:132- 148.

  9. Shimoni Y, Rattner JB. Type 1 diabetes leads to cytoskeleton changes that are reflected in insulin action on rat cardiac K+ currents. Am J Physiol Endocrinol Metab 2001;281:E575- E585.

  10. Ding An D, Brian Rodrigues. Role Changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006;291:H1489-H1506.

  11. van den Brom CE, Huisman MC, Vlasblom R, Boontje NM, Duijst S, Lubberink M, et al. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovascular Diabetology 2009;8:1-12.

  12. Bentley R. Glucose oxidase. In: Boyer PD, Lardy H, Myrbäck K. (eds). The Enzymes. 2nd ed. Vol 7. New York: Academic Press, 1963;567-586.

  13. Prophet Edna. Laboratory Methods in Histotechnology. Armed Forces Institute of Pathology, USA 1992;53-57, 132-133.

  14. Kumar LG, Rudbeck L. Education Guide. Immunhistochemical Staining Methods. Fifth Edition. Dako North America. Carpintería, California, USA, 2009;35-42 and 51-60.

  15. Like AA, Rossine AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976;193:415-417.

  16. Manjarrez GG, Herrera MR, Molina HA, Bueno SS, González RM, Hernandez RJ. Alteraciones en la síntesis de serotonina cerebral inducidas por diabetes mellitus insulinodependiente. Rev Invest Clin 1999;51:293-302.

  17. Manjarrez GG, Herrera MJR, Bueno SS, González RM, Hernández RJ. Cambios en la biosíntesis de serotonina cerebral en ratas con diabetes mellitus inducida por estreptozotocina: efecto del tratamiento. Rev Invest Clin 2000;52:509-516.

  18. Herrera R, Manjarrez G, Hernández J. Inhibition and kinetic changes of brain tryptophan-5-hydroxylase during insulindependent diabetes mellitus in the rat. Nutr Neurosci 2005;8:57-62.

  19. Vicario J, Licheri A, Gerardo L, Lofeudos C. Sinusoides y fistulas coronarias a cavidad ventricular izquierda. Presentación de un caso. Rev Fed Arg Cardiol 2004;33:236-239.

  20. Reese DE, Mikawa T, Bader DM. Development of the Coronary Vessel System. Circ Res 2002;91:761-768.

  21. Störk T, Möckel M, Eichstädt H. Persistent myocardial sinusoids of the left ventricle. Am J Cardiol 2002;89:489.

  22. Peraira JR, Burgueros M, Esteban I, García-Guereta L, Rubio MD, Álvarez-Ferreira FJ. Atresia pulmonar con septo íntegro asociada a estenosis aórtica severa. Rev Esp Cardiol 2003;56:1235-1238.

  23. Hausdorf G, Grävimphoff L, Keck EW. Effects of persisting myocardial sinusoids on left ventricular performance in pulmonary atresia with intact ventricular septum. Eur Heart J 1987;8:91-296.

  24. Pitkänen OP, Nuutila P, Raitakari OT, Rönnema T, Koskinse PJ, Lida H, et al. Coronary flow reserve is reduced in young men with IDDM. Diabetes. 1998;47:248-254.

  25. Cosyns B, Droogmans S, Hernot S, Degaillier C, Garbar C, Weytjens C, et al. Effect of streptozotocin-induced diabetes on myocardial blood flow reserve assessed by myocardial contrast echocardiography in rats. Cardiovas Diabetol 2008;7:26.doi:10.1186/1475-2840-7-26.

  26. Frang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543-567.

  27. Carly AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetes hearts. Biochim Biophys Acta 2005;1734:112-126.

  28. Bell DS. Diabetic cardiomyopathy: A unique entity or a complication of coronary artery disease? Diabetes Care 1995;18:708-714.

  29. Spector KS. Diabetic Cardiomyopathy. Clin Cardiol 1998;21:885-887.

  30. Codinach Huix P, Freixa Pamias R. Miocardiopatia diabética: concepto, función cardiaca y patogenia. An Med Interna (Madrid) 2002;19:313-320.

  31. Clausell N, Kalil P, Biolo A, Molossi S, Azevedo M. Increased Expression of Tumor Necrosis factor-a in Diabetic Macrovasculopathy. Cardiovasc Pathol 1999;8:145-151.

  32. Shimizu M, Umeda K, Sugihara N, Yoshio H, Ino H, Takeda R, et al. Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol 1993;46:32-36.

  33. Boudina S, Abel ED. Diabetic Cardiomyopathy Revisited. Circulation 2007;115:3213-3223.

  34. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, et al. Attenuation by Metallothionein of Early Cardiac Cell Death via Suppression of Mitochondrial Oxidative Stress Results in a Prevention of Diabetic Cardiomyopathy. J Am Coll Cardiol 2006;48:1688-1697.

  35. Christoffersen C, Hunter I, Jensen LA, Goetze PJ. Diabetes and the endocrine heart. Eur Heart J 2007;28:2427-2429.




2020     |     www.medigraphic.com